title: Red cell membrane during erythropoietin therapy in hemodialysis and in hemodiafiltration.
abstract: This study assessed the effect of recombinant human erythropoietin (r-HuEPO) on red cell membrane behaviour in patients undergoing hemodialysis (HD) and hemodiafiltration (HDF). We studied erythrocyte osmotic fragility (EOF), mechanical fragility (EMF) and deformability (ED) before and after r-HuEPO therapy in patients on conventional dialysis treatment with a cuprophan membrane and in subjects undergoing HDF with a polyacrylonitrile membrane. Non-uremic, non-anemic subjects were enrolled as controls. Red cell membrane defects were more evident in HD than in HDF; r-HuEPO seemed to improve deformability in both groups compared to controls (p less than 0.005) possibly through the great production of red cells during this therapy.
authors.affiliation: Division of Nephrology and Dialysis, San Martino Hospital, Genova, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Icardi
authors.forename: E
authors.initials: E
authors.lastname: Paoletti
authors.forename: G B
authors.initials: GB
authors.lastname: Traverso
authors.forename: C
authors.initials: C
authors.lastname: Sarchi
authors.forename: G
authors.initials: G
authors.lastname: Cappelli
authors.forename: G
authors.initials: G
authors.lastname: Molinelli
mesh_terms: D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D004907:Erythrocyte Deformability / Q000502:physiology; D004910:Erythrocyte Membrane / Q000502:physiology*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006440:Hemofiltration; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D009996:Osmotic Fragility / Q000502:physiology; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis
chemical_list: D008567:Membranes, Artificial; D011994:Recombinant Proteins; D004921:Erythropoietin